Literature DB >> 28985946

Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents.

Chad M Thompson1, Mina Suh2, Deborah M Proctor2, Laurie C Haws3, Mark A Harris4.   

Abstract

The determination of whether a chemical induces a specific cancer through a mutagenic or non-mutagenic mode of action (MOA) plays an important role in choosing between linear and nonlinear low-dose extrapolation to derive toxicity criteria. There is no formal framework from the U.S. EPA for determining whether environmental chemicals act through a mutagenic or non-mutagenic MOA; consequently, most such determinations are made on an ad hoc basis. Eastmond [Mutat Res 751 (2012)] recently conducted a systematic investigation of MOA determinations by U.S. and international regulatory agencies and organizations, and identified ten major factors that influence them, including toxicokinetics, in vivo genotoxicity in target organs, data quality, and evidence for alternative MOAs. We have used these ten factors to evaluate mutagenic vs. non-mutagenic MOA for gastrointestinal tumors induced by oral exposure to hexavalent chromium [Cr(VI)]. We also highlight similarities between Cr(VI) and other intestinal carcinogens previously determined to have non-genotoxic MOAs. Based on these analyses, we conclude that the MOA for Cr(VI) induced gastrointestinal tumors is non-mutagenic and that threshold risk assessment approaches are appropriate.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carcinogenicity; Genotoxicity; Hexavalent chromium; Mode of action; Risk assessment

Mesh:

Substances:

Year:  2017        PMID: 28985946     DOI: 10.1016/j.mrgentox.2017.08.004

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  5 in total

Review 1.  What is the meaning of 'A compound is carcinogenic'?

Authors:  Dieter Schrenk
Journal:  Toxicol Rep       Date:  2018-04-07

2.  Comparison of Gene Expression Responses in the Small Intestine of Mice Following Exposure to 3 Carcinogens Using the S1500+ Gene Set Informs a Potential Common Adverse Outcome Pathway.

Authors:  Grace A Chappell; Julia E Rager; Jeffrey Wolf; Milos Babic; Kyle J LeBlanc; Caroline L Ring; Mark A Harris; Chad M Thompson
Journal:  Toxicol Pathol       Date:  2019-09-26       Impact factor: 1.902

3.  Assessment of Mechanistic Data for Hexavalent Chromium-Induced Rodent Intestinal Cancer Using the Key Characteristics of Carcinogens.

Authors:  Grace A Chappell; Daniele S Wikoff; Chad M Thompson
Journal:  Toxicol Sci       Date:  2021-02-26       Impact factor: 4.849

4.  Crypt and Villus Transcriptomic Responses in Mouse Small Intestine Following Oral Exposure to Hexavalent Chromium.

Authors:  Grace A Chappell; Jeffrey C Wolf; Chad M Thompson
Journal:  Toxicol Sci       Date:  2022-02-28       Impact factor: 4.849

5.  Comparison of Toxicity and Recovery in the Duodenum of B6C3F1 Mice Following Treatment with Intestinal Carcinogens Captan, Folpet, and Hexavalent Chromium.

Authors:  Chad M Thompson; Jeffrey C Wolf; Alene McCoy; Mina Suh; Deborah M Proctor; Christopher R Kirman; Laurie C Haws; Mark A Harris
Journal:  Toxicol Pathol       Date:  2017-11-21       Impact factor: 1.902

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.